BioNER Studio · Biomedical Named Entity Recognition

Entities Extracted

—

Dominant Category

—

no entities

Inference Speed

—

Mean Confidence

0.0%

threshold ≥ 70%

Entity categories

Confidence threshold≥ 70%

50%99%

Resetting…Done

Sample abstracts

Oncology

NSCLC · EGFR · Osimertinib

Cardiology

AF · Apixaban · Warfarin

Neurology

Alzheimer's · Aβ · Lecanemab

Fetch by PubMed PMID

Try:

Clinical text

Osimertinib versus standard EGFR-TKI in previously untreated EGFR-mutated advanced non-small cell lung cancer BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion or L858R mutation respond to first-generation tyrosine kinase inhibitors, but acquired resistance mediated by the T790M mutation limits durability. METHODS: In this randomized, double-blind phase 3 trial, 556 patients with previously untreated EGFR-mutated advanced lung adenocarcinoma received osimertinib 80 mg once daily or a standard EGFR-TKI (gefitinib 250 mg once daily or erlotinib 150 mg once daily). Tumor response was assessed by computed tomography and brain MRI every 6 weeks. RESULTS: Median progression-free survival was 18.9 months with osimertinib versus 10.2 months with standard EGFR-TKI (hazard ratio 0.46). Responses were also observed in patients with central nervous system metastases. Grade 3 or higher adverse events, including diarrhea, rash, and interstitial lung disease, were less frequent with osimertinib. CONCLUSIONS: Osimertinib is an effective first-line therapy. Plasma ctDNA genotyping can detect resistance mutations and guide subsequent chemotherapy with cisplatin and pemetrexed.

Osimertinib versus standard EGFR-TKI in previously untreated EGFR-mutated advanced non-small cell lung cancer

BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion or L858R mutation respond to first-generation tyrosine kinase inhibitors, but acquired resistance mediated by the T790M mutation limits durability.

METHODS: In this randomized, double-blind phase 3 trial, 556 patients with previously untreated EGFR-mutated advanced lung adenocarcinoma received osimertinib 80 mg once daily or a standard EGFR-TKI (gefitinib 250 mg once daily or erlotinib 150 mg once daily). Tumor response was assessed by computed tomography and brain MRI every 6 weeks.

RESULTS: Median progression-free survival was 18.9 months with osimertinib versus 10.2 months with standard EGFR-TKI (hazard ratio 0.46). Responses were also observed in patients with central nervous system metastases. Grade 3 or higher adverse events, including diarrhea, rash, and interstitial lung disease, were less frequent with osimertinib.

CONCLUSIONS: Osimertinib is an effective first-line therapy. Plasma ctDNA genotyping can detect resistance mutations and guide subsequent chemotherapy with cisplatin and pemetrexed.

1,236 / 6,000 chars · 167 wordsCtrl/⌘ + Enter to run

Annotated Literature View

DISEASECHEMICALGENEANATOMYPROCEDURE

Run an analysis to see entities highlighted here.

Hover or keyboard-focus any highlighted entity to inspect its span, type and confidence.

Entity Distribution

Disease / Disorder0 · 0%
Drug / Chemical0 · 0%
Gene / Protein0 · 0%
Anatomy / Body Part0 · 0%
Procedure / Dosage0 · 0%

Entity Confidence Summary

Average—
Highest—
Lowest—

Run an analysis to see confidence statistics

Extracted Entities0

				Raw tag
Results will appear here after analysis.

Exports include the 0 rows currently shown (filters, threshold and search applied).